Consequently, PSMA-based imaging technologies for the detection of metastatic disease in advanced-stage prostate cancer patients were developed and PSMA-based radioligand therapy was introduced as a therapeutic regimen in metastasized prostate cancer[3–10]. Here, FOLH1 is linked to Familial prostate cancer.